Piper Sandler lowered the firm’s price target on Ryan Specialty (RYAN) to $35 from $43 and keeps a Neutral rating on the shares. The firm notes the company reported a beat versus consensus and Piper’s estimates driven by better-than-expected margins and organic growth. The firm thought the quarter was pretty good, but the 2026 organic growth and margin guidance was lowered substantially. Piper expects the stock to be down on the lower guidance and pessimistic tone on the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYAN:
- Ryan Specialty price target lowered to $39 from $41 at Barclays
- Wells downgrades Ryan Specialty to Equal Weight on below peer growth
- Ryan Specialty downgraded to Equal Weight from Overweight at Wells Fargo
- Ryan Specialty reports Q2 adjusted EPS 47c, consensus 43c
- Ryan Specialty sees FY26 organic revenue growth rate in mid-single digits